

# Amand F Schmidt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7816188/publications.pdf>

Version: 2024-02-01

61  
papers

3,052  
citations

279487

23  
h-index

189595

50  
g-index

79  
all docs

79  
docs citations

79  
times ranked

6120  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association analyses based on false discovery rate implicate new loci for coronary artery disease. <i>Nature Genetics</i> , 2017, 49, 1385-1391.	9.4	571
2	Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis. <i>PLoS Medicine</i> , 2016, 13, e1002179.	3.9	324
3	PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 97-105.	5.5	298
4	Linear regression and the normality assumption. <i>Journal of Clinical Epidemiology</i> , 2018, 98, 146-151.	2.4	296
5	Genetic drug target validation using Mendelian randomisation. <i>Nature Communications</i> , 2020, 11, 3255.	5.8	175
6	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. <i>The Cochrane Library</i> , 2017, 4, CD011748.	1.5	93
7	Mendelian randomization for studying the effects of perturbing drug targets. <i>Wellcome Open Research</i> , 2021, 6, 16.	0.9	90
8	Adjustment for index event bias in genome-wide association studies of subsequent events. <i>Nature Communications</i> , 2019, 10, 1561.	5.8	87
9	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 534-543.	5.5	84
10	Associations Between Measures of Sarcopenic Obesity and Risk of Cardiovascular Disease and Mortality: A Cohort Study and Mendelian Randomization Analysis Using the UK Biobank. <i>Journal of the American Heart Association</i> , 2019, 8, e011638.	1.6	75
11	Lipid lowering and Alzheimer disease risk: A mendelian randomization study. <i>Annals of Neurology</i> , 2020, 87, 30-39.	2.8	64
12	Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. <i>Nature Communications</i> , 2021, 12, 5640.	5.8	57
13	Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization. <i>Circulation</i> , 2022, 145, 1205-1217.	1.6	50
14	Mendelian randomization for studying the effects of perturbing drug targets. <i>Wellcome Open Research</i> , 2021, 6, 16.	0.9	48
15	Exploring interaction effects in small samples increases rates of false-positive and false-negative findings: results from a systematic review and simulation study. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 821-829.	2.4	44
16	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. <i>The Cochrane Library</i> , 2020, 2020, CD011748.	1.5	42
17	Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care settings. <i>Diabetologia</i> , 2022, 65, 644-656.	2.9	41
18	Prognostic factors of early metastasis and mortality in dogs with appendicular osteosarcoma after receiving surgery: An individual patient data meta-analysis. <i>Preventive Veterinary Medicine</i> , 2013, 112, 414-422.	0.7	40

#	ARTICLE	IF	CITATIONS
19	Circulating Fatty Acids and Risk of Coronary Heart Disease and Stroke: Individual Participant Data Meta-Analysis in Up to 16126 Participants. <i>Journal of the American Heart Association</i> , 2020, 9, e013131.	1.6	36
20	An electronic health records cohort study on heart failure following myocardial infarction in England: incidence and predictors. <i>BMJ Open</i> , 2018, 8, e018331.	0.8	31
21	Dissecting the IL6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2875-2884.	1.1	29
22	Impact of Selection Bias on Estimation of Subsequent Event Risk. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	28
23	Mendelian randomization with Egger pleiotropy correction and weakly informative Bayesian priors. <i>International Journal of Epidemiology</i> , 2018, 47, 1217-1228.	0.9	27
24	Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients. <i>Frontiers in Psychiatry</i> , 2020, 11, 38.	1.3	27
25	Justification of exclusion criteria was underreported in a review of cardiovascular trials. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 635-644.	2.4	23
26	Polygenic risk scores for coronary artery disease and subsequent event risk amongst established cases. <i>Human Molecular Genetics</i> , 2020, 29, 1388-1395.	1.4	23
27	Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 240.	0.7	22
28	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002471.	1.6	22
29	Long-term incidence and risk factors of cardiovascular events in Asian populations: systematic review and meta-analysis of population-based cohort studies. <i>Current Medical Research and Opinion</i> , 2019, 35, 291-299.	0.9	20
30	Triglyceride-containing lipoprotein sub-fractions and risk of coronary heart disease and stroke: A prospective analysis in 11,560 adults. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1617-1626.	0.8	19
31	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002470.	1.6	17
32	Obesity causes cardiovascular diseases: adding to the weight of evidence. <i>European Heart Journal</i> , 2020, 41, 227-230.	1.0	16
33	Human Genomics and Drug Development. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2022, 12, a039230.	2.9	16
34	No Clinically Relevant Effect of Heart Rate Increase and Heart Rate Recovery During Exercise on Cardiovascular Disease: A Mendelian Randomization Analysis. <i>Frontiers in Genetics</i> , 2021, 12, 569323.	1.1	15
35	Low-Density Lipoprotein Cholesterol Attributable Cardiovascular Disease Risk Is Sex Specific. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	15
36	Differences in interaction and subgroup-specific effects were observed between randomized and nonrandomized studies in three empirical examples. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 599-607.	2.4	14

#	ARTICLE	IF	CITATIONS
37	The median and the mode as robust meta-analysis estimators in the presence of small study effects and outliers. <i>Research Synthesis Methods</i> , 2020, 11, 397-412.	4.2	14
38	Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1827-1835.	1.1	13
39	Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics. <i>Nature Communications</i> , 2021, 12, 6120.	5.8	13
40	Tailoring treatments using treatment effect modification. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 355-362.	0.9	12
41	Adjusting for Confounding in Early Postlaunch Settings. <i>Epidemiology</i> , 2016, 27, 133-142.	1.2	11
42	Association of Factor V Leiden With Subsequent Atherothrombotic Events. <i>Circulation</i> , 2020, 142, 546-555.	1.6	11
43	Which dogs with appendicular osteosarcoma benefit most from chemotherapy after surgery? Results from an individual patient data meta-analysis. <i>Preventive Veterinary Medicine</i> , 2016, 125, 116-125.	0.7	7
44	Cochrane corner: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. <i>Heart</i> , 2018, 104, 1053-1055.	1.2	7
45	Re. <i>Epidemiology</i> , 2016, 27, e12.	1.2	6
46	Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia. <i>Atherosclerosis</i> , 2022, 340, 61-67.	0.4	6
47	Comments on "The use of propensity scores and observational data to estimate randomized controlled trial generalizability bias"™ by Taylor R. Pressler and Eloise E. Kaizar, <i>Statistics in Medicine</i> 2013. <i>Statistics in Medicine</i> , 2014, 33, 536-537.	0.8	5
48	Dementia in the older population is associated with neocortex content of serum amyloid P component. <i>Brain Communications</i> , 2021, 3, fcab225.	1.5	5
49	The impact of fatty acids biosynthesis on the risk of cardiovascular diseases in Europeans and East Asians: a Mendelian randomization study. <i>Human Molecular Genetics</i> , 2022, 31, 4034-4054.	1.4	5
50	Bayesian methods including nonrandomized study data increased the efficiency of postlaunch RCTs. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 387-396.	2.4	4
51	Adjusting for bias in unblinded randomized controlled trials. <i>Statistical Methods in Medical Research</i> , 2018, 27, 2413-2427.	0.7	4
52	When drug treatments bias genetic studies: Mediation and interaction. <i>PLoS ONE</i> , 2019, 14, e0221209.	1.1	4
53	Comparison of variance estimators for meta-analysis of instrumental variable estimates. <i>International Journal of Epidemiology</i> , 2016, 45, dyw123.	0.9	3
54	Chemotherapy effectiveness and mortality prediction in surgically treated osteosarcoma dogs: A validation study. <i>Preventive Veterinary Medicine</i> , 2016, 125, 126-134.	0.7	3

#	ARTICLE	IF	CITATIONS
55	Risk Factors and Prevalence of Dilated Cardiomyopathy in Sub-Saharan Africa: Protocol for a Systematic Review. <i>JMIR Research Protocols</i> , 2021, 10, e18229.	0.5	3
56	Establishing reference intervals for triglyceride-containing lipoprotein subfraction metabolites measured using nuclear magnetic resonance spectroscopy in a UK population. <i>Annals of Clinical Biochemistry</i> , 2021, 58, 47-53.	0.8	2
57	Unravelling the Difference Between Men and Women in Post-CABG Survival. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 768972.	1.1	2
58	The median and the mode as robust meta-analysis estimators in the presence of small-study effects and outliers. , 2020, 11, 397.		1
59	Cochrane corner: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. <i>Heart</i> , 2022, 108, 14-15.	1.2	1
60	Establishing reference intervals for triglyceride containing lipoprotein sub-fraction metabolites measured using nuclear magnetic resonance spectroscopy in a UK population. <i>Atherosclerosis</i> , 2020, 315, e95-e96.	0.4	0
61	Abstract 15527: Association Between Adrenergic Receptor Modulation and the Risk of Heart Failure: A Two-sample Mendelian Randomization Study. <i>Circulation</i> , 2020, 142, .	1.6	0